- Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-RL), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C studyWu, Y-L.; Zhao, J.; Hu, J.; Wu, J.; Xu, Y.; Yang, Z.; Liu, Z.; Jiang, L.; Chen, J.; Yu, Y.; Huang, M.; Dong, X.; Liu, L.; Feng, W.; Wu, L.; Cang, S.; Sun, J.; Xie, Q.; Chen, H-J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpressionYu, Y.; Dong, W.; Shi, Y.; Wu, R.; Yu, Q.; Ye, F.; Zhou, C.; Dong, X.; Li, X.; Li, Y.; Li, Z.; Pan, Y.; Shen, H.; Wu, D.; Xu, Z.; Wu, J.; Xu, N.; Qin, Y.; Li, J.; Lu, S.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION studyPaik, Paul K.; Garassino, Marina Chiara; Le, Xiuning; Thomas, Michael; Sakai, Hiroshi; Veillon, Remi; Smit, Egbert F.; Mazieres, Julien; Cortot, Alexis B.; Raskin, Jo; Viteri, Santiago; Yang, James Chih-Hsin; Ahn, Myung-Ju; Wu, Yi-Long; Zhao, Jun; Adrian, Svenja; Berghoff, Karin; Bruns, Rolf; Johne, Andreas; Felip, EnriquetaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 1
会议论文
Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
14阅读
